CytoSorbents Expands CytoSorb E.U. Distribution With WMC in the Netherlands

CytoSorbents Expands CytoSorb E.U. Distribution With WMC in the Netherlands 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 10/30/13 --  CytoSorbents
Corporation (OTCQB: CTSO), a critical care focused therapeutic device
company using blood purification to treat life-threatening illnesses,
announced the signing of an exclusive distribution agreement with WMC
Medical Supplies and Consultancy for distribution of CytoSorb(R) in
the Netherlands. This multi-year agreement is subject to annual
minimum guaranteed orders of CytoSorb(R) to maintain exclusivity.  
Mr. Eric Willemsen, CEO of WMC in the Netherlands, stated, "We
believe that our partnership with CytoSorbents will enable us to
address the growing serious problem of critical care illnesses in a
market where patients are getting older and sicker. CytoSorb(R) is a
very promising and easy to handle product that has been effective in
treating very sick patients in the intensive care unit." 
Dr. Phillip Chan, CEO of CytoSorbents Corporation, commented, "We are
pleased to be working with WMC on the launch of CytoSorb(R) in the
Netherlands. WMC's significant experience in marketing new medical
products through its established physician and hospital relationships
will help to facilitate market interest and sales of CytoSorb(R) in
this important country."  
The Netherlands has the 18th largest economy in the world and ranks
10th in gross domestic product per capita. The country has
approximately 17 million people, and its capital Amsterdam is well
known. The Netherlands offers its citizens a high level of medical
care, spending 9.3% of its GDP, or approximately $75 billion, on
healthcare. The people are serviced by 94 hospitals, of which 18 are
major university and top clinical centers. The average life
expectancy of its citizens is 78 years of age for men, and 82 years
of age for women.  
About WMC Medical Supplies and Consultancy  
WMC Medical Supplies and Consultancy was established in 2007, led by
an experienced, passionate and dedicated team that specializes in the
introduction and clinical support of innovative medical devices in
hospitals. The company also works with companies to support clinical
About CytoSorbents Corporation 
CytoSorbents Corporation is a critical care focused therapeutic
device company using blood purification to modulate the immune system
and fight multi-organ failure in life-threatening illnesses. Its
purification technology is based on biocompatible, highly porous
polymer beads that can actively remove toxic substances from blood
and other bodily fluids by pore capture and adsorption. CytoSorb(R),
the Company's flagship product, is approved in the European Union as
a safe and effective extracorporeal cytokine filter, designed to
reduce the "cytokine storm" that could otherwise cause massive
inflammation, organ failure and death in common critical illnesses
such as sepsis, burn injury, trauma, lung injury, and pancreatitis.
These are conditions where the mortality is extremely high, yet no
effective treatments exist. Additional information is available for
download on the Company's website: 
Forward-Looking Statements
 This press release includes
forward-looking statements intended to qualify for the safe harbor
from liability established by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press release
are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ
materially from those anticipated. These statements are based on
management's current expectations and assumptions and are naturally
subject to uncertainty and changes in circumstances. We caution you
not to place undue reliance upon any such forward-looking statements.
Actual results may differ materially from those expressed or implied
by the statements herein. Risk factors are detailed in the Company's
Form 10-K filed with the SEC on April 3, 2013, which is available at 
Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823 
Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222 
Valter Pinto
(914) 669-0222 x201 
Media Contact:
JQA Partners
Jules Abraham
(917) 885-7378 
Press spacebar to pause and continue. Press esc to stop.